TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30390884

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Dietary restriction
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ayurveda advice
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Consumption of night shade vegetables
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard diet of RA patients
Number of subjects: 141
Study: 26295379

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for chronic pain; details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite PROMIS symptom score; internal reliability (Cronbach's alpha=0.86) and construct validity confirmed.
Number of subjects: 0
Study: 24510678

Group type: EXPERIMENTAL
Intervention: H2/H2 carriers (n = 5)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cangrelor (specific receptor antagonist for P2Y12)
Number of subjects: 29

Group type: COMPARATOR
Intervention: VerifyNow assay
Number of subjects: 29
Study: 22691871

Group type: EXPERIMENTAL
Intervention: Individual counselling through 'The Healthy Skin Clinic' intervention program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional information (control group)
Number of subjects: 300
Study: 20164485

Group type: EXPERIMENTAL
Intervention: Essential Newborn Care training
Number of subjects: 119009

Group type: COMPARATOR
Intervention: Neonatal Resuscitation Program training
Number of subjects: 119009
Study: 17922978

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200 microg once daily in the evening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 400 microg twice daily (BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200-400 microg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15695959

Group type: EXPERIMENTAL
Intervention: Physical therapies and shoulder arthrography with intra-articular steroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapies alone
Number of subjects: 0
Study: 12801569

Group type: EXPERIMENTAL
Intervention: Density Gradient Centrifugation (DGC)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Wash only
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 311
Study: 10047935

Group type: EXPERIMENTAL
Intervention: 2.5 mg/d of deprenyl
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 mg/d of deprenyl
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers, mean age 63.1 +/- 1.2 years)
Number of subjects: 14
Study: 7571176

Group type: EXPERIMENTAL
Intervention: ESWL in situ
Number of subjects: 180

Group type: COMPARATOR
Intervention: Retrograde manipulation before ESWL
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Retrograde manipulation for stones < 8 mm
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Auxiliary procedures (DJ catheter placement)
Number of subjects: 180
Study: 2076733

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 128
Study: 7267221

Group type: EXPERIMENTAL
Intervention: Group 1: Blood phenylalanine target 1.0 to 5.4 mg/100 ml
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Group 2: Blood phenylalanine target 5.5 to 9.9 mg/100 ml
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined treatment groups
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Treatment factors
Number of subjects: 132
Study: 31217380

Group type: EXPERIMENTAL
Intervention: High-intensity ergometer exercise at 80% VO2peak for 60 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (rest for 60 min)
Number of subjects: 9
Study: 30955702

Group type: EXPERIMENTAL
Intervention: real-tDCS
Number of subjects: 56

Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 56
Study: 26907843

Group type: EXPERIMENTAL
Intervention: Morning Training Group (MTG, 07:00-08:00 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evening Training Group (ETG, 17:00-18:00 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 20
Study: 24170180

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Lurasidone 80-120 mg/day
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day and 80-120 mg/day
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 505
Study: 22424912

Group type: EXPERIMENTAL
Intervention: Immediate-release hydromorphone (IR) 5 times/day
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Once-daily hydromorphone extended-release (ER) at full dose
Number of subjects: 148

Group type: COMPARATOR
Intervention: Once-daily hydromorphone extended-release (ER) at half dose
Number of subjects: 148
Study: 19022580

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SPT)
Number of subjects: 50
Study: 17226906

Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg bid for 7 d every month) plus dietary fiber supplementation (at least 20 gr/d)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Dietary fiber supplementation alone
Number of subjects: 307
Study: 15128011

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen-progestin combination)
Number of subjects: 20000
Study: 12373029

Group type: EXPERIMENTAL
Intervention: Increased intracranial pressure
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: Recurrent cerebral ischemia
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: Fever >38 degrees C
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: Severe arterial hypertension
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: Brain stem infarction and large-artery atherosclerosis
Number of subjects: 3866
Study: 9638982

Group type: EXPERIMENTAL
Intervention: Medical therapy for gastrointestinal bleeding
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Surgery for gastrointestinal bleeding
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Embolization for gastrointestinal bleeding
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Surgery for peritonitis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall mortality in patients with gastrointestinal emergencies
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prognostic factors
Number of subjects: 36
Study: 8046277

Group type: EXPERIMENTAL
Intervention: High‐force, high‐velocity, low‐amplitude manipulation procedure
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Low‐force, high‐velocity, low‐amplitude procedure
Number of subjects: 201

Group type: COMPARATOR
Intervention: Educational lectures on lower back pain
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 201
Study: 2648190

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Butorphanol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 64
Study: 29553002

Group type: EXPERIMENTAL
Intervention: Stereotype threat condition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50
Study: 26508098

Group type: EXPERIMENTAL
Intervention: Cognitive dual-task (CDT) training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Executive function (EF) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24590644

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 4 weeks)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 645
Study: 22749044

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg once daily) + Salmeterol (50 μg twice daily) (T + S)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Salmeterol + Fluticasone (50/500 μg twice daily) (S + F)
Number of subjects: 309
Study: 20053144

Group type: COMPARATOR
Intervention: Fosinopril alone (F group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fosinopril+indapamide (F/I group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fosinopril alone after conversion from Fosinopril+indapamide (F/I group)
Number of subjects: 124
Study: 18514974

Group type: EXPERIMENTAL
Intervention: PCV-9
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 16319156

Group type: EXPERIMENTAL
Intervention: Intraarticular sodium hyaluronate (SH) 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraarticular glucocorticoids (triamcinolone acetonide; TA) 10 mg
Number of subjects: 60
Study: 12873934

Group type: EXPERIMENTAL
Intervention: Alprostadil 0.2 micro g. kg(‐1). min(‐1) (20 mL/h) for 60 min
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline 20 mL/h for 60 min (Control)
Number of subjects: 32
Study: 10526249

Group type: EXPERIMENTAL
Intervention: Finasteride 5mg once daily for 12 months
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flutamide 250mg twice daily for 12 months
Number of subjects: 110
Study: 8879439

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (two 600-mg tablets once per day for 8 weeks)
Number of subjects: 10
Study: 8503391

Group type: EXPERIMENTAL
Intervention: Cisapride (15 mg/day for 14 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls (n = 6)
Number of subjects: 14
Study: 3689013

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg intrarectally every 6-8 hours until postoperative day 3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (16 patients who did not receive indomethacin)
Number of subjects: 14
Study: 31920015

Group type: EXPERIMENTAL
Intervention: Pneumonia patients
Number of subjects: 14736

Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged < 70 years
Number of subjects: 14736

Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged 70-79 years
Number of subjects: 14736

Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged 80-89 years
Number of subjects: 14736

Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged ≥ 90 years
Number of subjects: 14736

Group type: EXPERIMENTAL
Intervention: Men pneumonia patients
Number of subjects: 14736

Group type: EXPERIMENTAL
Intervention: Women pneumonia patients
Number of subjects: 14736

Group type: COMPARATOR
Intervention: Non-pneumonia patients
Number of subjects: 14736
Study: 30026562

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) group (n=15) performed one immersion at 10°C for 20 min post-exercise and every 24 h for 72 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n=15) remained seated during corresponding periods
Number of subjects: 30
Study: 28775197

Group type: EXPERIMENTAL
Intervention: 90% kanuka honey
Number of subjects: 950

Group type: COMPARATOR
Intervention: 5% aciclovir cream
Number of subjects: 950
Study: 25541248

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (Futurabond M, 1-SE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesive (Solobond M, 2-ER)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Four-step etch-and-rinse adhesive (Syntac classic, 4-ER)
Number of subjects: 40
Study: 23953929

Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21788129

Group type: EXPERIMENTAL
Intervention: PSA screening with a cut-off of 3.0-4.0 ng/ml at a 2-7 year interval
Number of subjects: 61604
Study: 19114384

Group type: EXPERIMENTAL
Intervention: Web-based alcohol education program
Number of subjects: 3216

Group type: COMPARATOR
Intervention: Control group (completed a survey and knowledge test)
Number of subjects: 3216
Study: 16960268

Group type: COMPARATOR
Intervention: Dexamethasone 5 mg iv with epidural injection of 0.25% bupivacaine 8 mL and normal saline 2 mL (Control)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Normal saline 2 mL iv with epidural injection of 0.25% bupivacaine 8 mL and dexamethasone 5 mg in normal saline 2 mL (D1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Normal saline 2 mL iv with epidural injection of dexamethasone 5 mg in normal saline 10 mL (D2)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dexamethasone groups (D1, D2)
Number of subjects: 94
Study: 15485402

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 830

Group type: COMPARATOR
Intervention: Control (matching placebo for fosinopril)
Number of subjects: 830

Group type: COMPARATOR
Intervention: Control (matching placebo for pravastatin)
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Framingham risk score <20%
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Framingham risk score
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Combination of Framingham score and urinary albumin excretion
Number of subjects: 830
Study: 11011783

Group type: EXPERIMENTAL
Intervention: 8.5 g of supplemental arginine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 17 g of supplemental arginine
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0 g of supplemental arginine (Control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 8.5 g and 17 g of supplemental arginine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All arginine supplementation groups
Number of subjects: 32
Study: 8707022

Group type: EXPERIMENTAL
Intervention: Propafenone (mean daily dose of 13 ± 1.5 mg/Kg; Group A: 102 patients)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sotalol (mean daily dose of 3 ± 0.4 mg/Kg; Group B: 106 patients)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (Group C: 92 patients)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sotalol compared to Propafenone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Propafenone and Sotalol compared to Placebo
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control Group (Placebo)
Number of subjects: 300
Study: 1901437

Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (patients with inferior wall AMI)
Number of subjects: 44
Study: 6626636

Group type: EXPERIMENTAL
Intervention: Auditory stimulus A (counted stimulus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory stimulus B (not-to-be-counted stimulus)
Number of subjects: 0
Study: 31086250

Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 30
Study: 28918362

Group type: EXPERIMENTAL
Intervention: High Volume (HV) Resistance Training
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Low Volume (LV) Resistance Training
Number of subjects: 376

Group type: COMPARATOR
Intervention: Both groups (HV and LV)
Number of subjects: 376
Study: 25856221

Group type: EXPERIMENTAL
Intervention: Group B (Scarborough Fair Diet)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group A (generic range of vegetables/herbs/fruit)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group C (usual diet)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 50
Study: 22817664

Group type: EXPERIMENTAL
Intervention: Low-intensity, pulsed, electromagnetic fields (PEF) treatment for 10 minutes (mean intensity 1.5 mW)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment for 10 minutes
Number of subjects: 42
Study: 21059637

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) with one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard dose BEP (cisplatin, etoposide, and bleomycin)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard dose BEP
Number of subjects: 131
Study: 19717851

Group type: EXPERIMENTAL
Intervention: Beta-blocker continuation
Number of subjects: 169

Group type: COMPARATOR
Intervention: Beta-blocker discontinuation
Number of subjects: 169
Study: 17438089

Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 74
Study: 14766592

Group type: EXPERIMENTAL
Intervention: Sourdough bread made from a mixture of wheat (30%) and nontoxic oat, millet, and buckwheat flours started with selected lactobacilli after 24 hours of fermentation.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baker's yeast bread containing ca. 2 g of gluten.
Number of subjects: 17
Study: 11701466

Group type: EXPERIMENTAL
Intervention: Niacin-ER (1 g)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Niacin-ER (2 g)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Gemfibrozil (1.2 g)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Niacin-ER and Gemfibrozil
Number of subjects: 139
Study: 9399024

Group type: EXPERIMENTAL
Intervention: Plasma total antioxidant capacity (TAOC)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Dietary intake of water spinach
Number of subjects: 728

Group type: COMPARATOR
Intervention: Presence of hypertension or cardiovascular disease
Number of subjects: 728
Study: 7983641

Group type: EXPERIMENTAL
Intervention: Low dose prednisone (5 to 10 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No prednisone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low dose prednisone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy elderly male controls
Number of subjects: 36
Study: 3185283

Group type: EXPERIMENTAL
Intervention: Pure porcine insulin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mixed bovine/porcine insulin
Number of subjects: 105
Study: 31898296

Group type: EXPERIMENTAL
Intervention: Randomized-marker method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single imputation using state space representation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple imputation based on regression
Number of subjects: 0
Study: 31548792

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 6 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Moderate-Intensity Training (MIT) for 6 weeks
Number of subjects: 7
Study: 29390529

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (Er:YAG laser and SRP)
Number of subjects: 27
Study: 24595735

Group type: EXPERIMENTAL
Intervention: Peer mentoring to promote exercise
Number of subjects: 10
Study: 22893351

Group type: EXPERIMENTAL
Intervention: Dental amalgam exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dental amalgam exposure
Number of subjects: 0
Study: 21193190

Group type: EXPERIMENTAL
Intervention: LT4 treatment (50 μg administered from the first day of controlled ovarian stimulation for IVF/ICSI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LT4 treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 18589404

Group type: COMPARATOR
Intervention: THC
Number of subjects: 15

Group type: COMPARATOR
Intervention: CBD
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16595232

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching
Number of subjects: 14

Group type: COMPARATOR
Intervention: Acidified Tyrode's hatching
Number of subjects: 14
Study: 14632720

Group type: COMPARATOR
Intervention: Insulin/gliclazide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Insulin/repaglinide
Number of subjects: 80
Study: 10939691

Group type: EXPERIMENTAL
Intervention: Remifentanil and isoflurane
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Remifentanil and enflurane
Number of subjects: 854

Group type: COMPARATOR
Intervention: Total Intravenous Anaesthesia (TIVA) with propofol
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol
Number of subjects: 854
Study: 10437193

Group type: EXPERIMENTAL
Intervention: Combination of acupuncture, pilose antler essence injection to acupoints, and oral administration of Chinese materia medica
Number of subjects: 279
Study: 8256404

Group type: EXPERIMENTAL
Intervention: Catheterless technique (no ureteral or urethral catheters)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ureteral and urethral catheters
Number of subjects: 34
Study: 3534849

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg/Hydrochlorothiazide 12.5 mg once daily (o.d.)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/Hydrochlorothiazide 25 mg once daily (o.d.)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30048788

Group type: EXPERIMENTAL
Intervention: Intraoperative neurophysiological monitoring (IONM) change
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no IONM change)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Risk factor analysis for IONM change
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Postoperative outcomes related to IONM change
Number of subjects: 79
Study: 27519180

Group type: EXPERIMENTAL
Intervention: Clinician-led group
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Peer-led group
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Internet version of the prevention program
Number of subjects: 680

Group type: COMPARATOR
Intervention: Educational video
Number of subjects: 680
Study: 25059854

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 22482373

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 8 mcg/kg (N8)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 4 mcg/kg (N4)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Epidural saline (SF)
Number of subjects: 45